人工呼吸器関連肺炎(VAP):パイプラインレビュー2019下半期

【英語タイトル】Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120331)・商品コード:GDATA9120331
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:169
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Ventilator Associated Pneumonia (VAP) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) – Pipeline Review, H2 2019, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 6, 7, 1, 8, 2 and 1 respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ventilator Associated Pneumonia (VAP) – Overview
Ventilator Associated Pneumonia (VAP) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ventilator Associated Pneumonia (VAP) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ventilator Associated Pneumonia (VAP) – Companies Involved in Therapeutics Development
Aridis Pharmaceuticals Inc
AstraZeneca Plc
Bioversys AG
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
Evaxion Biotech ApS
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics Plc
Nosopharm SAS
Polyphor AG
Shionogi & Co Ltd
Spero Therapeutics Inc
Tetraphase Pharmaceuticals Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
Ventilator Associated Pneumonia (VAP) – Drug Profiles
(avibactam + aztreonam) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(avibactam sodium + ceftazidime) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + tazobactam sodium) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + VNRX-5133) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + zidebactam) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cilastatin sodium + imipenem + relebactam) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-401 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbekacin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BV-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cefiderocol sulfate tosylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBX-003 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBX-004 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eravacycline dihydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVXB-4 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfomycin disodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iclaprim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nacubactam – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOSO-2G – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Panaecin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
panobacumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-7001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qn-2251 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections and Ventilator Associated Pneumonia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-206 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvratoxumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tedizolid phosphate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telavancin hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tosatoxumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ventilator Associated Pneumonia (VAP) – Dormant Projects
Ventilator Associated Pneumonia (VAP) – Discontinued Products
Ventilator Associated Pneumonia (VAP) – Product Development Milestones
Featured News & Press Releases
Oct 15, 2019: New study reveals superiority of Vibativ over Vancomycin in select patients with Bacterial Pneumonia
Oct 02, 2019: Shionogi reports positive results from Cefiderocol phase III study in adults with pneumonia caused by gram-negative pathogens
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals Inc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Bioversys AG, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by CytaCoat AB, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Plc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Evaxion Biotech ApS, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics Plc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Nosopharm SAS, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor AG, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Spero Therapeutics Inc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2019
Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, H2 2019
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2019
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Ventilator Associated Pneumonia (VAP) - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2019 10
Number of Products under Development by Companies, H2 2019 11
Number of Products by Top 10 Targets, H2 2019 17
Number of Products by Stage and Top 10 Targets, H2 2019 17
Number of Products by Top 10 Mechanism of Actions, H2 2019 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019 19
Number of Products by Routes of Administration, H2 2019 21
Number of Products by Stage and Routes of Administration, H2 2019 21
Number of Products by Molecule Types, H2 2019 23
Number of Products by Stage and Molecule Types, H2 2019 23

【掲載企業】

Aridis Pharmaceuticals Inc
AstraZeneca Plc
Bioversys AG
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
Evaxion Biotech ApS
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics Plc
Nosopharm SAS
Polyphor AG
Shionogi & Co Ltd
Spero Therapeutics Inc
Tetraphase Pharmaceuticals Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd

★調査レポート[人工呼吸器関連肺炎(VAP):パイプラインレビュー2019下半期] (コード:GDATA9120331)販売に関する免責事項を必ずご確認ください。
★調査レポート[人工呼吸器関連肺炎(VAP):パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆